BMO reiterates Cal-Maine Foods stock rating on supply outlook

BMO reiterated Market Perform on Cal-Maine Foods with a $75 price target, saying it is incrementally more constructive but remains cautious amid oversupplied egg markets; it sees potential for supply to rebalance through production cuts or renewed HPAI. In fiscal Q1 2027, Cal-Maine reported an adjusted EPS loss of $1.23 versus a $0.77 consensus loss and revenue of $539.6 million versus $587.8 million expected, with a net loss of $58.6 million compared with net income of $199.3 million a year earlier. Stephens cut its price target from $80 to $70 and maintained Equal Weight, citing weak margins and low egg prices.

Analysis

The key debate is whether weak egg economics are finally self-correcting or whether investors are trying to call the supply turn too early. Low prices can eventually force flock reductions, but biological production cycles make that response lagged; near-term earnings can deteriorate further before supply tightens. A book-value anchor is therefore weak protection if earnings power and asset returns are still resetting.

HPAI is a two-sided catalyst, not an unqualified bull case: an outbreak can tighten industry supply and lift realized prices, while also creating production and execution risk for affected producers. The net benefit to Cal-Maine depends on its exposure, which the article does not establish. The recent earnings miss raises the bar for evidence that either supply mechanism is improving; an analyst’s more constructive tone is not that evidence.

Over days, the low-share-price narrative may attract value buyers, but that support can fail if estimates continue down. Over 1–3 months, watch company commentary on flock decisions and industry supply indicators, alongside realized pricing and gross-margin direction. Over 6–18 months, sustained supply discipline could restore earnings, but renewed disease or rapid restocking could reverse the price recovery. Contrarian point: the market may be underestimating how long oversupply persists, while also overestimating how reliably disease-related price spikes translate into producer earnings.

Key Decisions for Investors

• No immediate directional position: treat the valuation discount as an alert, not a floor. Reassess after the next operating update or earnings report confirms improving realized prices and gross-margin direction.
• For a tactical long, require evidence of supply contraction or sustained pricing improvement first; use a defined-risk position rather than buying solely on price-to-book. The thesis is falsified by continued margin deterioration or evidence that industry supply remains elevated.
• If already long CALM, avoid adding ahead of confirmation and consider reducing exposure if guidance or subsequent results show further earnings deterioration. A renewed HPAI event alone is not sufficient confirmation because company-level production exposure and net impact are unknown.
• Track industry flock/supply data, CALM’s production and realized-price commentary, and the next gross-margin result. A persistent mismatch—weak margins despite tighter supply indicators, or supply growth despite low prices—would challenge the respective recovery thesis.